Renal Cell Carcinoma in Patients With a Personal or Family History of Hematologic Malignancies

Volume 13, Issue 6 June 2015 Janice P. Dutcher, MD, and Peter H. Wiernik, MD The authors are affiliated with the Cancer Research Foundation of New York in […]

Non–Clear Cell Renal Cell Carcinoma, Part 2: Therapy

Volume 13, Issue 6 June 2015 Loana B. Valenca, MD, Michelle S. Hirsch, MD, PhD, Toni K. Choueiri, MD, and Lauren C. Harshman, MD The authors are […]

Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and Developing Novel Therapeutic Strategies

Volume 13, Issue 6 June 2015 Isabelle Gingras, MD, Hatem A. Azim Jr, MD, PhD, Michail Ignatiadis, MD, PhD, and Christos Sotiriou, MD, PhD The authors are […]

The Future of Kidney Cancer Treatment

Volume 13, Issue 6 June 2015 Daniel J. George, MD Associate Professor of Medicine and Surgery Director of Genitourinary Oncology Program Department of Medicine Duke University […]

Imaging Techniques for Hepatocellular Carcinoma

Volume 13, Issue 6 June 2015 Claude Sirlin, MD Professor of Radiology University of California, San Diego San Diego, California H&O Is there a standardized protocol […]

New Therapies for Polycythemia Vera

Volume 13, Issue 6 June 2015 Srdan Verstovsek, MD, PhD Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center […]

MET as a Drug Target

Volume 13, Issue 6 June 2015 Ravi Salgia, MD, PhD Professor of Medicine Director, Thoracic Oncology Program Vice Chair, Translational Sciences Department of Medicine, Section of […]

Intermittent Dosing in Melanoma

Volume 13, Issue 6 June 2015 Martin McMahon, PhD Assistant Director of Professional Education Co-Leader, Developmental Therapeutics Program UCSF Helen Diller Family Comprehensive Cancer Center Efim […]

The “ASC(ST)O” Meeting

Volume 13, Issue 6 June 2015 In another week, I will be heading off to Chicago for the “ASC(ST)O” meeting. Fewer and fewer of my colleagues […]

June News

Kathryn Turner, PhD FDA Expands Ramucirumab Indications to Include Metastatic Colorectal Cancer The US Food and Drug Administration (FDA) has approved the use of ramucirumab (Cyramza, […]

Back to Archive